Promising therapeutic antibodies from other species typically go through the process of humanization before they reach human patients.
Humanization involves altering its amino acid sequence such that it more closely resembles a human antibody. While this is a common
method used to minimize immunogenicity risk, humanization remains a substantial technical barrier. Twist Bioscience has developed a
humanization platform that combines highly precise DNA synthesis with machine learning (ML) to improve the process to enable faster,
more efficient, and ultimately more productive antibody engineering.